Science AI Journal
Medicine · Research topic

Open research questions in Autoimmune Bullous Skin Diseases

130 gap statements mined from Autoimmune Bullous Skin Diseases papers in our 4.5M-paper local library, which holds 957 papers on the topic — drawn mostly from each paper's own stated research gap, future-work, challenge and limitation notes, and its abstract. The ones listed below are a selection still marked open; each names the study that raised it, with a DOI link where the paper has one.

Choosing where to publish on Autoimmune Bullous Skin Diseases? See the ranked Medicine journals.

What the literature leaves open

  • There is insufficient evidence on the safety and effectiveness of influenza vaccination in B-cell-mediated autoimmune diseases such as pemphigus. There is no controlled research on the efficacy of the influenza vaccine in pemphigus. The underlying mechanisms of pemphigus relapse following vaccination are unclear.

    The efficacy and safety of influenza vaccine in pemphigus in the COVID-19 era: A randomized trial · 2026 · DOI

  • There is a paucity of consolidated information evaluating KP in AIBD. The role of KP in AIBD development is less understood, particularly in relation to triggers, manifestations, and treatment strategies. There is a need for a comprehensive review of reported cases of KP in AIBD to improve patient outcomes and quality of life.

    Koebner phenomenon in autoimmune bullous dermatoses: a scoping review of documented cases · 2026 · DOI

  • Challenges in assessment caused by hair coverage and limited photographic visibility. Subjective evaluation of erythema severity and the presence or absence of ulceration may be more difficult to standardize across assessors.

    Determining the reliability of existing pemphigus severity scores for tele-dermatology · 2026 · DOI

  • Limited understanding of the molecular basis of pemphigus vulgaris. Difficulty in identifying biomarkers for pemphigus vulgaris.

    Targeted metabolomics investigation of serum levels of fatty acid metabolites in pemphigus vulgaris patients and healthy individuals · 2026 · DOI

  • The study notes the need for further studies to elucidate the pathogenesis of canine pemphigus foliaceus. The study identifies the challenge of understanding the molecular mechanisms of canine PF disease development. The study notes the limitation of previous studies on canine PF, including the limited number of samples and the lack of next-generation sequencing data.

    Microarray Gene Expression Analysis of Lesional Skin in Canine Pemphigus Foliaceus · 2024 · DOI

  • The study notes that previous studies evaluating immune markers of canine PF patients are limited. The study identifies a need for further studies with canine PF lesional skin using next-generation sequencing and the development of canine keratinocyte/skin explant PF models.

    Microarray Gene Expression Analysis of Lesional Skin in Canine Pemphigus Foliaceus · 2024 · DOI

  • While antibody concentration is routinely used to assess disease activity, the role of antibody avidity in PV monitoring has not been elucidated.

    Anti‐Desmoglein 3 Avidity Correlates Better With Pemphigus Vulgaris Severity Than Anti‐Desmoglein 3 Concentration · 2026 · DOI

  • Management of high- and low-risk MMP in this setting and the potential oncologic trade-offs remain poorly defined.

    Mucous Membrane Pemphigoid After Anti‐ PD ‐1 Therapy: Risk‐Stratified Management and Treatment Outcomes · 2026 · DOI

  • Topical calcineurin inhibitors have shown promise as steroid-sparing agents in localized disease, though evidence remains limited.

    Optimizing Local Treatment in Pemphigus and Pemphigoid: Current Evidence and Unmet Needs · 2026 · DOI

  • Antiseptics such as chlorhexidine may aid in infection control, though clinical data are sparse.

    Optimizing Local Treatment in Pemphigus and Pemphigoid: Current Evidence and Unmet Needs · 2026 · DOI

  • Proteolytic enzymes, including matrix metalloproteinase-9 (MMP-9) and granzyme B, contribute to dermal-epidermal separation, but their expression in human skin lesions is not fully quantified.

    Tissue Levels of MMP‐9 and Granzyme B in Patients With Bullous Pemphigoid: A Case–Control Study · 2026 · DOI

  • However, the clinical trial landscape remains fragmented, and a comprehensive overview of emerging therapies is lacking.

    The Emerging Therapeutic Landscape of Bullous Pemphigoid: A Systematic Registry‐Based Analysis of Clinical Trials (2015–2025) · 2026 · DOI

  • However, the role and underlying molecular mechanisms of miR-125b-5p in PV remain unclear.

    MiR-125b-5p promotes pemphigus vulgaris pathogenesis by modulating desmosome structures · 2026 · DOI

  • Evidence-based criteria for determining which patients require laryngoscopic examination are lacking.

    Predicting Laryngeal Involvement in Pemphigus Vulgaris Using a Clinical Risk Score · 2026 · DOI

  • It is most often described during treatment of melanoma, lung cancer, and renal cell carcinoma, whereas reports in gynecologic oncology, and specifically during lenvatinib plus pembrolizumab (LP) therapy, remain scarce.

    Immune checkpoint inhibitor-related bullous pemphigoid with negative direct immunofluorescence during pembrolizumab plus lenvatinib therapy: a case report · 2026 · DOI

  • However, evidence in this respect is limited, and the underlying immune mechanisms remain unknown.

    Lymphocyte Transformation Tests and Patch Tests to Identify Drugs Potentially Associated With Bullous Pemphigoid Development · 2025 · DOI

  • It remains unclear whether it represents a distinct entity due to antibody class-switching within an altered immunological environment, or a transitional form in the pemphigus spectrum arising from inflammation-associated epitope spreading Identified target molecules include desmoglein-1, desmoglein-3, desmocollin-1, and desmocollin-2.

    Arciform Erythematous Plaques With Hypopyon Sign · 2025 · DOI

  • The mechanisms by which PV antibodies induce loss of cohesion in keratinocytes are not fully understood.

    Data-driven image analysis to determine antibody-induced dissociation of cell–cell adhesion and antibody pathogenicity in pemphigus · 2025 · DOI

  • The sensitivity constraints of GC-based lipidomic in complex biological samples limited the detection of some metabolites. The study did not assess nutritional status. The study had a relatively small sample size of 50 participants.

    Targeted metabolomics investigation of serum levels of fatty acid metabolites in pemphigus vulgaris patients and healthy individuals · 2026 · DOI

  • These findings extend prior work on psychiatric burden in AIBDs and suggest trauma-related psychopathology may be underrecognized.

    Association of Comorbid Trauma and Stressor‐Related Disorders in Pemphigus and Pemphigoid: A Case‐Control Study · 2026 · DOI

  • Laminin-332, an epidermis-specific extracellular matrix protein composed of α3, β3, and γ2 subunits, has poorly defined subunit-specific phenotypes This case showed severe, extensive cutaneous involvement with isolated anti–laminin-332 autoantibodies.

    Anti–Laminin‐332 Subepidermal Autoimmune Blistering Disease With Extensive Cutaneous Involvement: A Case Report · 2026 · DOI

  • Mucosal lesions were limited to the oral and nasal mucosa, without ocular, laryngeal, esophageal, or vulvar lesions.

    Anti–Laminin‐332 Subepidermal Autoimmune Blistering Disease With Extensive Cutaneous Involvement: A Case Report · 2026 · DOI

  • Although limited by the low sample size, positive LTT patients showed a trend toward clinical improvement when the implicated drug was discontinued.

    Lymphocyte Transformation Tests and Patch Tests to Identify Drugs Potentially Associated With Bullous Pemphigoid Development · 2025 · DOI

  • While no reports exist regarding biologics for ASIA syndrome, anti-TNF drugs have been successfully used in recent years to treat silicone granulomas.

    Sustained response to anti‐ TNF therapy in ASIA syndrome triggered by vaccination and filler · 2025 · DOI

  • Certain PDAI components showed moderate reliability due to challenges in assessment - ODSS activity showed moderate reliability due to subjective evaluation - The study was conducted in a hospital-based setting - The study had a limited sample size of 80 patients - The study did not validate the scoring systems for use in other…

    Determining the reliability of existing pemphigus severity scores for tele-dermatology · 2026 · DOI

Most-cited papers in Autoimmune Bullous Skin Diseases

Most recent work

Find a gap in your own Autoimmune Bullous Skin Diseases sub-topic

This page shows what the Autoimmune Bullous Skin Diseases literature already flags as unresolved. To narrow it to your specific question, search the Research Gap Finder: the search is free with a free account and lists the papers closest to your topic first. Unlocking that topic (50 credits, charged once) fills the comparison table from our 4.5M-paper local library and writes the gaps from its rows.

Open the Research Gap Finder →

Related topics in Medicine

Artificial Intelligence in Healthcare and Education
2,876 open questions
Substance Abuse Treatment and Outcomes
2,034 open questions
Dementia and Cognitive Impairment Research
1,793 open questions
Cancer Immunotherapy and Biomarkers
1,619 open questions
Sports Performance and Training
1,473 open questions
Liver Disease Diagnosis and Treatment
1,423 open questions
Ferroptosis and cancer prognosis
1,343 open questions
Physical Activity and Health
1,253 open questions
Open questions raised by papers listed on this page include: (1) There is no controlled research on the efficacy of the influenza vaccine in pemphigus (“The efficacy and safety of influenza vaccine in pemphigus in the COVID-19 era:…”, 2026); (2) There is a paucity of consolidated information evaluating KP in AIBD (“Koebner phenomenon in autoimmune bullous dermatoses: a scoping review of…”, 2026); (3) While antibody concentration is routinely used to assess disease activity, the role of antibody avidity in PV monitoring has not been elucidated (“Anti‐Desmoglein 3 Avidity Correlates Better With Pemphigus Vulgaris Severity…”, 2026); (4) Topical calcineurin inhibitors have shown promise as steroid-sparing agents in localized disease, though evidence remains limited (“Optimizing Local Treatment in Pemphigus and Pemphigoid: Current Evidence and…”, 2026); (5) The clinical trial landscape remains fragmented, and a comprehensive overview of emerging therapies is lacking (“The Emerging Therapeutic Landscape of Bullous Pemphigoid: A Systematic…”, 2026). 130 gap statements have been mined from Autoimmune Bullous Skin Diseases papers in our 4.5M-paper local library, which holds 957 papers on the topic; the gaps come from whichever of those papers state one. They are mostly the research gaps the authors state and the papers' abstracts, plus future-work, limitations and challenges passages. The ones listed below are a selection still marked open; each names the study that raised it, with a DOI link where the paper has one, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 120,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? Acceptance odds for top, mid and open/emerging journals, in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck for prior publication across 7 sources and our local library.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

How Pre-Check worksHow AI Review works

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.